About Allergy Therapeutics
Allergy Therapeutics is a company based in Worthing (United Kingdom) founded in 1998. The company has 612 employees as of June 30, 2024. Allergy Therapeutics offers products and services including Allergy Treatments, Research Services, and Adjuvant Systems. Allergy Therapeutics operates in a competitive market with competitors including Altimmune, Biological E, Stallergenes Greer, IgGenix and Vaxart, among others.
- Headquarter Worthing, United Kingdom
- Employees 612 as on 30 Jun, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Allergy Therapeutics Plc
-
Annual Revenue
$69.82 M (USD)-7.36as on Jun 30, 2024
-
Net Profit
-$50.87 M (USD)6.63as on Jun 30, 2024
-
EBITDA
-$39.74 M (USD)-2.6as on Jun 30, 2024
-
Latest Funding Round
$13.85 M (USD), Post-IPO
Jul 19, 2018
-
Investors
Not available
-
Employee Count
612
as on Jun 30, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Allergy Therapeutics
Allergy Therapeutics is a publicly listed company on the LSE with ticker symbol AGY in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Allergy Therapeutics
Allergy Therapeutics offers a comprehensive portfolio of products and services, including Allergy Treatments, Research Services, and Adjuvant Systems.
Develops convenient therapies for allergy and immune disorders
Provides expertise in allergy treatment innovation
Offers systems for enhancing immune responses
People of Allergy Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Allergy Therapeutics
Investments & Acquisitions by Allergy Therapeutics
Investment portfolio details for Allergy Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Allergy Therapeutics
Detailed financials for Allergy Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Allergy Therapeutics Comparisons
Peer comparison for Allergy Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Allergy Therapeutics
Allergy Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Altimmune, Biological E, Stallergenes Greer, IgGenix and Vaxart, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| Locked | Locked | Locked |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| Locked | Locked | Locked |
Allergen immunotherapies for respiratory allergies are developed.
|
|
| Locked | Locked | Locked |
Therapeutic solutions for food allergies are developed via antibody platforms.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for treating multiple infectious diseases
|
Detailed competitors of Allergy Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Allergy Therapeutics
Complete news archive for Allergy Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Allergy Therapeutics
Allergy Therapeutics was founded in 1998 and raised its 1st funding round 11 years after it was founded.
Allergy Therapeutics is headquartered in Worthing, United Kingdom.
As of Jun 30, 2024, the latest employee count at Allergy Therapeutics is 612.
Annual revenue of Allergy Therapeutics is $69.82M as on Jun 30, 2024.
Founded in 1998 and based in Worthing, United Kingdom, operations in the biopharmaceutical sector are centered on research and development of allergy treatments. Subcutaneous immunotherapy and modified allergen tyrosin-absorbed therapies are focused on for diagnosing and treating allergy-related conditions. Aluminum-free vaccines and diagnostic tools are produced to address these health issues.
Allergy Therapeutics's top competitors include Biological E, Stallergenes Greer and IgGenix.
Allergy Therapeutics offers Allergy Treatments, Research Services, and Adjuvant Systems.
Yes, Allergy Therapeutics is publicly traded on LSE under the ticker symbol AGY.
The ticker symbol of Allergy Therapeutics is AGY on LSE.